A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats

Xenobiotica

Volumn 42, Issue 1, 2012, Pages 75-85

  Jones, Rhys M ^a   Harrison, Anthony ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Absorption; Inhaled; Lung; Oratracheal; Pharmacokinetics; Prediction

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE; FORMOTEROL; SALBUTAMOL; SALMETEROL; TOFIMILAST; UK 432097;

ADULT; ANIMAL EXPERIMENT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PHARMACOKINETICS; PREDICTION; RAT; REVIEW;

ADENOSINE; ADMINISTRATION, INHALATION; ALBUTEROL; ANDROSTADIENES; ANIMALS; BIOSTATISTICS; BRONCHODILATOR AGENTS; BUDESONIDE; ETHANOLAMINES; HUMANS; MALE; PHARMACOKINETICS; RATS;

EID: 82955205868     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.626465     Document Type: Review

References (43)

1. Anjilvel S, Asgharian B. (1995). A multiple-path model of particle deposition in the rat lung. Fundam Appl Toxicol 28:41-50.
2. Banker MJ, Clark TH, Williams JA. (2003). Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967-974. (Pubitemid 36523442)
3. Bennett JA, Harrison TW, Tattersfeld AE. (1999). Te contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic efects. Eur Respir J 13:445-448. (Pubitemid 29086848)
4. Biddescombe MF, Melchor R, Mak VHF, Marriott RJ, Taylor AJ, Short MD and Spiro SG. (1993). Te lung deposition of salbutamol, directly labeled with technetium-99m, delivered by pressurized metered dose and dry powder inhalers. Int J Pharm 91:111-121. (Pubitemid 23159814)
5. Boddy A, Edwards P, Rowland M. (1989). Binding of sulfonamides to carbonic anhydrase: infuence on distribution within blood and on pharmacokinetics. Pharm Res 6:203-209. (Pubitemid 19121722)
6. Borgström L, Olsson B, Torsson L. (2006). Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med 19:473-483. (Pubitemid 46067766)
7. Brindley C, Falcoz C, Mackie AE, Bye A. (2000). Absorption kinetics after inhalation of futicasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy volunteers. Clin Pharmacokinet 39:1-8.
8. Byron P. (1990). Respiratory Drug Delivery. CRC press P113.
9. Clark DJ, Lipworth BJ. (1996). Lung bioavailability of chlorofuorocarbon free, dry powder and chlorofuorocarbon containing formulations of salbutamol. Br J Clin Pharmacol 41:247-249. (Pubitemid 26079185)
10. Crapo JD, Young SL, Fram EK, Pinkerton KE, Barry BE, Crapo RO. (1983). Morphometric characteristics of cells in the alveolar region of mammalian lungs. Am Rev Respir Dis 128:42-46.
11. Crompton GK. (1991). Dry powder inhalers: Advantages and limitations. J Aerosol Med 4:151-156.
12. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
13. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. (2007). Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35:1766-1780. (Pubitemid 47481568)
14. DeSesso JM, Williams AC. (2008). Contrasting the gastrointestinal tracts of mammals: Factors that infuence absorption. Annual reports in medicinal chemistry, published by elsevier science & technology 43:353-371
15. Edsbäcker S, Johansson CJ. (2006). Airway selectivity: An update of pharmacokinetic factors afecting local and systemic disposition of inhaled steroids. Basic Clin Pharmacol Toxicol 98:523-536.
16. Gabrielson J, Weiner D. (2000). Pharmacokinetic and pharmaco-dynamic data analysis: Concepts and applications. Stockholm, Sweden: Swedish Pharmaceutical Press. pp. 163-164.
17. Gehr P, Mwangi DK, Ammann A, Maloiy GM, Taylor CR, Weibel ER. (1981). Design of the mammalian respiratory system. V. Scaling morphometric pulmonary difusing capacity to body mass: Wild and domestic mammals. Respir Physiol 44:61-86. (Pubitemid 11111495)
18. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K. (2009). Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533.
19. Kastl S, Kotschenreuther U, Hille B, Schmidt J, Gepp H, Hohenberger W. (2004). Simplifcation of rat intubation on inclined metal plate. Adv Physiol Educ 28:29-32.
20. Kwon Y. (2001). Handbook of essential pharmacokinetics, pharmacodynamics and drug metabolism for industrial scientists. New York: Kluwer academic/plenum publishers.
21. Lahelma S, Kirjavainen M, Kela M, Herttuainen J, Vahteristo M, Silvasti M, Ranki-Pesonen M. (2004). Equivalent lung deposition of budesonide in vivo: A comparison of dry powder inhalers using a pharmacokinetic method. Br J Clin Pharmacol 59:167-173. (Pubitemid 40208852)
22. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. (2000). Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J Pharm Pharmaceut Sci 86:584-590. (Pubitemid 27203406)
23. Lecaillon JB, Kaiser G, Palmisano M, Morgan J, Della Cioppa G. (1999). Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. Eur J Clin Pharmacol 55:131-138. (Pubitemid 29196266)
24. Lipworth BJ, Clark DJ. (1997). Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices. Eur J Clin Pharmacol 53:47-49. (Pubitemid 27430029)
25. Manchee GR, Barrow A, Kulkarni S, Palmer E, Oxford J, Colthup PV, Maconochie JG, Tarbit MH. (1993). Disposition of salmeterol xinafoate in laboratory animals and humans. Drug Metab Dispos 21:1022-1028. (Pubitemid 23348338)
26. Mantell S, Jones RM, Trevethick M. (2010). Design and application of locally delivered agonists of the adenosine A2A receptor. Expet Rev Clin Pharmacol 3:55-72.
27. Meyer T, Brand P, Ehlich H, Köbrich R, Meyer G, Riedinger F, Sommerer K, Weuthen T, Scheuch G. (2004). Deposition of Foradil P in human lungs: Comparison of in vitro and in vivo data. J Aerosol Med 17:43-49. (Pubitemid 38520672)
28. McGinnity D F, Collington J, Austin RP, Riley RJ. (2007). Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 8:463-479. (Pubitemid 47603410)
29. Patton JS, Fishburn CS, Weers JG. (2004). Te lungs as a portal of entry for systemic drug delivery. Proc Am Torac Soc 1:338-344.
30. Plopper CG. (1983). Comparative morphologic features of bronchiolar epithelial cells. Te Clara cell. Am Rev Respir Dis 128:37-41.
31. Schanker LS, Less MJ. (1977). Lung pH and pulmonary absorption of nonvolatile drugs in the rat. Drug Metab Dispos 5:174-178. (Pubitemid 8321949)
32. Schanker LS, Mitchell EW, Brown RA Jr. (1986). Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection. Drug Metab Dispos 14:79-88. (Pubitemid 16152318)
33. Sinha VK, De Buck SS, Fenu LA, Smit JW, Nijsen M, Gilissen RA, Van Peer A, Lavrijsen K, Mackie CE. (2008). Predicting oral clearance in humans: How close can we get with allometry? Clin Pharmacokinet 47:35-45. (Pubitemid 350260887)
34. Smith JH, Williams H. (2006). Introduction to the principles of drug design and action. Florida, USA: CRC press, Taylor & Francis group P68.
35. Tang H, Mayersohn M. (2005). A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33:1297-1303. (Pubitemid 41196972)
36. Tayab ZR, Hochhaus G. (2005). Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: Application to targeted pulmonary delivery systems. Expert Opin Drug Deliv 2:519-532. (Pubitemid 41683225)
37. Torsson L, Edsbäcker S, Conradson TB. (1994). Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 7:1839-1844. (Pubitemid 24337357)
38. Torsson L, Edsbäcker S, Källén A, Löfdahl CG. (2001). Pharmacokinetics and systemic activity of futicasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 52:529-538.
39. Tronde A, Nordén B, Jeppsson AB, Brunmark P, Nilsson E, Lennernäs H, Bengtsson UH. (2003). Drug absorption from the isolated perfused rat lung-correlations with drug physico-chemical properties and epithelial permeability. J Drug Target 11:61-74. (Pubitemid 36527397)
40. van den Berg BT, Braat MC, van Boxtel CJ. (1998). Pharmacokinetics and efects of formoterol fumarate in healthy human subjects after oral dosing. Eur J Clin Pharmacol 54:463-468. (Pubitemid 28418813)
41. Ward JK, Dow J, Dallow N, Eynott P, Milleri S, Ventresca GP. (2000). Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man-no evidence of enantioselective lung metabolism. Br J Clin Pharmacol 49:15-22. (Pubitemid 30050482)
42. Warheit DB. (1989). Interspecies comparisons of lung responses to inhaled particles and gases. Crit Rev Toxicol 20:1-29. (Pubitemid 19190677)
43. Winkler J, Hochhaus G, Derendorf H. (2004). How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Torac Soc 1:356-363.